KalVista Pharma

Forecast & Rating7 analysts currently cover KalVista Pharma, with about 14.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $28.60, about 5.9% upside from the current price of $27.00. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 7.4% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on KalVista Pharma's outlook. Data as of Jun 11, 2026; for reference only and not investment advice.